

This is a repository copy of 5-Aminolevulinic acid-mediated fluorescence diagnosis of colon cancer: A histopathological comparison of fluorescent and non-fluorescent tumours.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/109831/

Version: Accepted Version

Article:

Goldsworthy, M, Tinkler-Hundal, E, Maisey, T et al. (5 more authors) (2016) 5-Aminolevulinic acid-mediated fluorescence diagnosis of colon cancer: A histopathological comparison of fluorescent and non-fluorescent tumours. European Journal of Surgical Oncology, 42 (11). S240-S240. ISSN 0748-7983

https://doi.org/10.1016/j.ejso.2016.07.091

Copyright © 2016 Published by Elsevier Ltd. This is an author produced version of an abstract published in EJSO - European Journal of Surgical Oncology.

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



5-aminolevulinic acid-mediated fluorescence diagnosis of colon cancer: a histopathological comparison of fluorescent and non-fluorescent tumours

<u>Matthew A Goldsworthy</u>¹, Emma Tinkler-Hundal², Thomas Maisey¹, Nicholas P West², Gemma Gossedge¹, Helen Andrew¹, Gregory W Taylor¹, David G Jayne¹

Background

5-aminolevulinic acid (5-ALA) selectively accumulates in cancer cells and is metabolised in the mitochondria to the fluorophore protoporphyrin IX. The GLiSten trial evaluated 5-ALA as a fluorescent probe for intraoperative detection of colon cancer and lymph node metastases. Only 13 of 40 cases showed fluorescence, suggesting a fundamental difference between fluorescent and non-fluorescent cancers. The aim of this study was to investigate whether differences in fluorescence were due to tumour cellularity, in particular T cell infiltration, which may be of prognostic significance.

Methods

Primary tumour tissue was available from 30 patients. The density of tumour cells, vascularity and stromal compartment size were quantified using digitally scanned tissue sections stained with haematoxylin and eosin. A set of 300 random points was superimposed onto each tumour image. The structure indicated by each point was then categorised as tumour, stroma, vessel or other. The proportions of tumour and vessel points gave the tumour cell density and vessel density respectively. The relative size of the stromal compartment was given by the tumour to stroma ratio. A tissue section was also stained for the T cell marker CD3 by immunohistochemistry. Percentage staining was quantified in three high-density fields using the Nuance imaging system.

Results

We were unable to detect any difference between fluorescent and non-fluorescent cancers in terms of tumour cell density (difference in means 3.7%; P=0.452), vessel density (difference in means 0.17%; P=0.684), tumour-stroma ratio (difference in mean ratios 0.12; P=0.934), or T cell count (difference in means 0.92%; P=0.726). Furthermore, comparisons of the distributions

¹ Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, UK

² Leeds Institute of Cancer and Pathology, University of Leeds, UK